Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) (pGGO)

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

With the advent of CT screening for lung cancer, there is an increase in the detection of pulmonary lesions with focal pure ground-glass opacity (pGGO). The pure Ground-glass opacities can be caused by normal expiration, partial filling of air spaces, partial collapse of alveoli, interstitial thickening, inflammation, oedema, fibrosis, and lepidic proliferation of neoplasm. Precise details of the natural history of focal pure GGO are still largely unclear. A number of differential diagnoses are possible, including inflammatory disease, focal scar, atypical adenomatous hyperplasia (AAH), and adenocarcinoma in situ. Some of pGGOs remained stable over a considerable time. A long doubling time for pGGOs is already known. Therefore, the strategy of treatment for focal pure GGO lesions is still undecided. The major issue is whether or not the doctors should treat these patients at all or wait until the first sign of a solid lesion developes which may take many years.

The purpose of this study is to determine if the ablation therapy is safe and effective for the pulmonary pGGO.

Condition or disease	Intervention/treatment	Phase
Pulmonary Lesions	Procedure: cryotherapy or radiofrequency ablation	Phase 3

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	100 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity
Study Start Date :	September 2011
Estimated Primary Completion Date :	October 2014
Estimated Study Completion Date :	December 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: ablation; Cryoablation or Radiofrequency ablation for the pGGO	Procedure: cryotherapy or radiofrequency ablation; Cryoablation or Radiofrequency ablation is performed under CT image guidance.
No Intervention: Follow up CT scann; The patients will receive follow up with CT scan every 6-9 months.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. The changing of the lesion [ Time Frame: 3 years ]

   To determine the efficacy rate of CT image guided ablation for pulmonary focal pGGO.

   To determine the feasibility and safety of CT image guided ablation in patients with pulmonary pGGO.

Secondary Outcome Measures :

1. The side effect of the therapy. [ Time Frame: 3 years ]
   Intra and post-operative complications rates. Quality-of-life assessment

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	20 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• The lesion(s) treated with ablation must be =< 2.0 cm in greatest dimension
• All patients are required to have been evaluated in a multi-disciplinary tumor conference to ensure that the lesion is suitable for Image-guided percutaneous ablation
• Platelet count ≥ 100 x 109/L
• International normalized ratio (INR) < 1.5
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• A signed study specific consent form is required

Exclusion Criteria:

• Direct evidence of regional or distant metastases,or synchronous primary or prior malignancy in the past 5 years
• Unable to lie flat or has respiratory distress at rest
• Uncontrolled coagulopathy or bleeding disorders
• Evidence of active systemic, pulmonary, or pericardial infection
• Women who are pregnant or breastfeeding
• Patients with poor pulmonary function

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Weisheng Chen, MD	+8618960826090	weishengmd@hotmail.com

Locations

China, Fujian
Dongfang Hospital	Recruiting
Fuzhou, Fujian, China, 350025
Contact: Yonggang Liang +8659122859888 ext 59388 war_ren@163.com

Sponsors and Collaborators

Dongfang Hospital Affiliated to Beijing University of Chinese Medicine

Investigators

Principal Investigator:	Weisheng Chen, MD	Dongfang Hospital Affiliated to Beijing University of Chinese Medicine

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Chen Weisheng, The vice chief of the Thoracic Division, Dongfang Hospital
ClinicalTrials.gov Identifier:	NCT01429649 History of Changes
Other Study ID Numbers:	kj2011001
First Posted:	September 7, 2011
Last Update Posted:	September 7, 2011
Last Verified:	September 2011

Keywords provided by Chen Weisheng, Dongfang Hospital:

pure pulmonary ground glass opacity